Co-founder and CEO announced he will step down from his role and the board by the end of 2026.
: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments
The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights:
: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .
: Introduced next-generation automated flow cell lines and strengthened quality assurance to ISO 13485 standards.
